Use of L-carnitine in general medical practice

Download full text PDF
Issue: 
4
Year: 
2019

Professor Zh. Sizova, MD; Professor E. Shikh, MD; A. Makhova, Candidate of Medical Sciences I.M. Sechenov First Moscow State Medical University (Sechenov University)

The paper presents the results of a number of experimental and clinical studies proving the prospects for using L-carnitine in the clinic of internal diseases. Due to its antioxidant and antihypoxant properties, L-carnitine used in addition to the main etiopathogenetic therapy is prescribed by cardiologists, nephrologists, neurologists, and gerontologists. The experimental studies previously conducted by the authors showed no effect of L-carnitine on cytochrome P450 3A4 activity, which lowers the risk of P450 (CYP) 3A4 metabolic drug interactions. When used as part of comprehensive pharmacotherapy, L-carnitine has an increased safety profile in comorbid patients taking the drug.

Keywords: 
cardiology
L-carnitine
cytochrome P450 (CYP) 3А4
chronic heart failure
myocardial infarction
chronic renal failure
drug interactions
antioxidant
antihypoxant



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Kukes V.G., Sychev D.A. Personalizirovannaja meditsina: novye vozmozhnosti dlja povyshenija bezopacnocti fapmakotepapii // Remedium. – 2010; 10: 38–40 [Kukes V.G., Sychev D.A. Personalized medicine: new possibilities to improve the safety of pharmacotherapy // Chem. – 2010; 10: 38–40 (in Russ.)].
  2. Maxova A.A. Vlijanie nagpyzochnyx doz vitaminov gruppy B na fapmakokinetiky i fapmakodinamiky NPVP. Dis. ... kand. med. nayk. M., 2010; 107 s. [Makhova AA. Influence of therapeutic doses of vitamins B on the pharmacokinetics and pharmacodynamics of the NSAIDs. Diss. ... PhD. M., 2010; 107 p. (in Russ.)].
  3. Rebouche C Carnitine. In: Shils M.E., Shike M., Ross A.C., Caballero B., Cousins R.J., eds. Modern Nutrition in Health and Disease. 10th ed. / Philadelphia: Lippincott, Williams & Wilkins, 2006; 537–44.
  4. Rebouche C. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism // Ann. NY Acad. Sci. – 2004; 1033: 30–41.
  5. De Grandis D., Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabeic neuropathy. A long-term, randomised, doubleblind, placebo-controlled study // Drugs RD. – 2002; 3 (4): 223–31.
  6. Gross C., Henderson L., Savaiano D. Uptake of L-carnitine, D-carnitine and acetyl-L-carnitine by isolated guinea-pig enterocytes // Biochim Biophys Acta. – 1986; 886 (3): 425–33.
  7. Foster D. The role of the carnitine system in human metabolism // Ann. NY Acad. Sci. – 2004; 1033: 1–16.
  8. Astashkin E.I., Glezer M.G. Rol' L-karnitina v energetichesokm obmene kardiomiotsitov i lechenii zabolevanij serdechno-sosudistoj sistemy // Kardiologija i serdechno-sosudistaja hirurgija. – 2012; 6 (2): 58–65 [Astashkin E.I., Glezer M.G. Effect of L-carnitine on oxydative stress at cardiovascular diseases // Cardiology and Cardiovascular Surgery. – 2012; 6 (2): 58–65 (in Russ.)].
  9. Lombard K., Olson A., Nelson S. et al. Carnitine status of lactoovovegetarians and strict vegetarian adults and children // Am. J. Clin. Nutr. – 1989; 50 (2): 301–6.
  10. Nezu J., Tamai I., Oku A. et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter // Nat Genet. – 1999; 21 (1): 91–4.
  11. Stanley C. Carnitine deficiency disorders in children // Ann. NY Acad. Sci. – 2004; 1033: 42–51.
  12. Seim H., Eichler K., Kleber H. L(-)-Carnitine and its precursor, gamma- butyrobetaine. In: Kramer K., Hoppe P., Packer L., eds. Nutraceuticals in Health and Disease Prevention / New York: Marcel Dekker, Inc, 2001; 217–56.
  13. Pons R., De Vivo D. Primary and secondary carnitine deficiency syndromes // J. Child Neurol. – 1995; 10 (Suppl. 2): 8–24.
  14. Calvani M., Benatti P., Mancinelli A. et al. Carnitine replacement in end-stage renal disease and hemodialysis // Ann. NY Acad. Sci. – 2004; 1033: 52–66.
  15. Food and Nutrition Board, Institute of Medicine. Vitamin C. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids / Washington D.C.: National Academy Press, 2000; 95–185.
  16. Costell M., O'Connor J., Grisolia S. Age-dependent decrease of carnitine content in muscle of mice and humans // Biochem. Biophys. Res. Commun. – 1989; 161 (3): 1135–43.
  17. Hagen T., Ingersoll R., Wehr C. et al. Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity // Proc. Natl. Acad. Sci. USA. – 1998; 95 (16): 9562–6.
  18. Pesce V., Fracasso F., Cassano P. et al. Acetyl-L-carnitine supplementation to old rats partially reverts the age- related mitochondrial decay of soleus muscle by activating peroxisome proliferator-activated receptor gamma coactivator-1alpha-dependent mitochondrial biogenesis // Rejuvenation Res. – 2010; 13 (2–3): 148–51.
  19. Gomez L., Heath S., Hagen T. Acetyl-l-carnitine supplementation reverses the age-related decline in carnitine palmitoyltransferase 1 (CPT1) activity in interfibrillar mitochondria without changing the l-carnitine content in the rat heart // Mech. Ageing Dev. – 2012; 133 (2–3): 99–106.
  20. Hagen T., Liu J., Lykkesfeldt J. et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress // Proc. Natl. Acad. Sci. USA. – 2002; 99 (4): 1870–5.
  21. Liu J., Head E., Gharib A. et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alphalipoic acid // Proc. Natl. Acad. Sci. USA. – 2002; 99 (4): 2356–61.
  22. Davini P., Bigalli A., Lamanna F. et al. Controlled study on L-carnitine therapeutic efficacy in post-infarction // Drugs Exp. Clin. Res. – 1992; 18 (8): 355–65.
  23. Xue Y., Wang L., Liu H. et al. L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction // Cardiovasc. Drugs Ther. – 2007; 21 (6): 445–8.
  24. Iyer R., Gupta A., Khan A. et al. Does left ventricular function improve with L-carnitine after acute myocardial infarction? // J. Postgrad. Med. – 1999; 45 (2): 38–41.
  25. Colonna P., Iliceto S. Myocardial infarction and left ventricular remodeling: results of the CEDIM trial. Carnitine Ecocardiografia Digitalizzata Infarto Miocardico // Am. Heart J. – 2000; 139 (2 Pt. 3): 124–30.
  26. Iliceto S., Scrutinio D., Bruzzi P. et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial // J. Am. Coll. Cardiol. – 1995; 26 (2): 380–7.
  27. Tarantini G., Scrutinio D., Bruzzi P. et al. Metabolic treatment with L-Carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial // Cardiology. – 2006; 106 (4): 215–23.
  28. Semigolovskij N.Ju. Vertsinskij E.K., Azanov B.A. i dr. Polozhitel'nye inotropnye svojstva levokarnitina pri sindrome malogo vybrosa u bol'nyh ostrym infarktom miokarda // Kardiologija i serdechno-sosudistaja hirurgija. – 2013; 3: 43–6 [Semigolovskiy N.Yu., Vertinskiy E.K., Azanov B.A. et al. Positive inotropic properties of levocarnitine in low ejection syndrome among patients wiht acute myocardial infarction // Cardiology and Cardiovascular Surgery. – 2013; 3: 43–6 (in Russ.)].
  29. Glezer M.G., Kiseleva A.E., Astashkin E.I. Vlijanie L-karnitina na dispersiju intervala QT u patsientov s ostrym koronarnym sindromom // Kardiologija. – 2015; 55 (3): 4–9 [Gleser M.G., Kiseleva A.E., Astashkin E.I. The effect of L-carnitine on the dispersion of the QT interval in patients with acute coronary syndrome // Cardiology. – 2015; 55 (3): 4–9 (in Russ.)].
  30. Glezer M.G., Kiseleva A.E., Astashkin E.I. Vlijanie L-karnitina na ChCC i QTc u patsientov s ostrym koronarnym sindromom // Serdtse. – 2015; 14 (2/82): 78–84 [Glezer M.G., Kiseleva A.E., Astashkin E.I. Effect of L-carnitine on CV and QTc in patients with acute coronary syndrome // The Heart. – 2015; 14 (2/82): 78–84 (in Russ.)].
  31. Glezer M.G., Kiseleva A.E., Prokof'eva E.B. i dr. Vlijanie L-karnitina na ehokardiograficheskie pokazateli u patsientov s ostrym koronarnym sindromom // Serdechnaja nedostatochnost'. – 2015; 16 (4): 234–40 [Glezer M.G., Kiseleva A.E., Prokofieva E.B. et al. Effect of L-carnitine on echocardiographic parameters in patients with acute coronary syndrome // Heart Failure J. – 2015; 16 (4): 234–40 (in Russ.)].
  32. Astashkin E.I., Glezer M.G. Vlijanie L-karnitina na oksidativnyj stress pri serdechno-sosudistyh zabolevanijah // Med. sovet. – 2016; 10: 94–100 [Astashkin E.I., Glezer M.G. The effect of L-carnitine on oxidative stress in cardiovascular diseases // Medical advice. – 2016; 10: 94–100 (in Russ.)].
  33. Astashkin E.I., Glezer M.G., Orehova N.S. i dr. Vlijanie L-karnitina na obrazovanie radikalov kisloroda fagotsitami krovi patsientov s postinfarktnym kardiosklerozom // Kardiovaskuljarnaja terapija i profilaktika. – 2016; 15 (5): 28–32 [Astashkin E.I., Glezer M.G., Orekhova N.S. et al. Influence of L-carnitine on reactive oxygen species production by blood phagocytes in postinfarction cardiosclerosis patients // Cardiovascular therapy and prevention. – 2016; 15 (5): 28–32 (in Russ.)].
  34. Rizos I. Threeyear survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration // Am. Heart J. – 2000; 139 (2 Pt. 3): 120–3.
  35. Xiaolong Song, Huiyan Qu, Zongguo Yang et al. Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials // BioMed Research International. – 2017; 2017: Article ID 6274854, 11 p. DOI: 10.1155/2017/6274854.
  36. Cacciatore L., Cerio R., Ciarimboli M. et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study // Drugs Exp. Clin. Res. – 1991; 17 (4): 225–35.
  37. Cherchi A., Lai C., Angelino F. et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo controlled crossover study // Int. J. Clin. Pharmacol. Ther. Toxicol. – 1985; 23 (10): 569–72.
  38. Iyer R., Khan A., Gupta A. et al. L-carnitine moderately improves the exercise tolerance in chronic stable angina // J. Assoc. Physicians India. – 2000; 48 (11): 1050–2.
  39. DiNicolantonio J., Lavie C., Fares H. et al. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and metaanalysis // Mayo Clin. Proc. – 2013; 88 (6): 544–51.
  40. Guarnieri G., Situlin R., Biolo G. Carnitine metabolism in uremia // Am. J. Kidney Dis. – 2001; 38 (4 Suppl. 1): 63–7.
  41. Hurot J., Cucherat M., Haugh M. et al. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review // J. Am. Soc. Nephrol. – 2002; 13 (3): 708–14.
  42. Kazmi W., Obrador G., Sternberg M. et al. Carnitine therapy is associated with decreased hospital utilization among hemodialysis patients // Am. J. Nephrol. – 2005; 25 (2): 106–15.
  43. Weinhandl E., Rao M., Gilbertson D. et al. Protective effect of intravenous levocarnitine on subsequent-month hospitalization among prevalent hemodialysis patients, 1998 to 2003 // Am. J. Kidney Dis. – 2007; 50 (5): 803–12.
  44. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation // Am. J. Kidney Diseases. – 2000; 35 (6 Suppl. 2): 1–140.
  45. Eknoyan G., Latos D., Lindberg J. Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference // Am. J. Kidney Dis. – 2003; 41 (4): 868–76.
  46. Schreiber B. Safety of oral carnitine in dialysis patients // Semin Dial. – 2002; 15 (1): 7.
  47. Wei X.-J., Han M., Wei G.-C. et al. Prognostic value of cerebrospinal fluid free fatty acid levels in patients with acute ischemic stroke // Frontiers in Human Neuroscience. – 2015; 9: 402. DOI: 10.3389/fnhum.2015.00402.
  48. Golovkin V., Zuev A., Privalova M. i dr. Kognitivnye narushenija i kardiorespiratornaja disfunktsija pri distsirkuljatornoj entsefalopatii s kardiotserebral'nym sindromom // Vrach. – 2018; 29 (4): 51–3 [Golovkin V., Zuev A., Privalova M. et al. Cognitive impairment and cardiorespiratory dysfunction in dyscirculatory encephalopathy with cardiocerebral syndrome // Vrach (The Doctor). – 2018; 29 (4): 51–3 (in Russ.)]. DOI: 10.29296/25877305-2018-04-09.
  49. Gusev E.I., Kuzin V.M., Kolesnikova T.N. i dr. Karnitin – veduschij faktor regeneratsii nervnoj tkani // Meditsinskij informatsionnyj vestnik. – 1999 (fevral'): 11–23 [Gusev E., Kuzin V.M., Kolesnikova T.N. Carnitine is a leading factor in the regeneration of nervous tissue // Medical Information Bulletin. – 1999 (February): 11–23 (in Russ.)].
  50. Bodyhov M.K., Stahovskaja L.V., Salimov K.A. i dr. Otsenka bezopasnosti i effektivnosti preparata «El'kar» (levokarnitin) u patsientov v ostrom periode ishemicheskogo insul'ta v karotidnoj sisteme // RMZh. Nevrologija. – 2011; 11: 3–6 [Bodikhov M.K., Stakhovskaya L.V., Salimov K.A. et al. Evaluation of the safety and efficacy of the drug Elkar (l-carnitine) in patients with acute ischemic stroke in the carotid system // RMZh. Neurology. – 2011; 11: 3–6 (in Russ.)].
  51. Chichanovskaja L.V., Bahareva O.N., Sorokina K.B. Issledovanie bezopasnosti i effektivnosti L-karnitina u bol'nyh v rannem vosstanovitel'nom periode ishemicheskogo insul'ta // Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. – 2017; 12 (Vyp. 2): 65–9 [Chichanovskaya L.V., Bakhareva O.N., Sorokina K.B. The study of the safety and efficacy of L-carnitine in patients in the early recovery period of ischemic stroke // J. Neurology and Psychiatry named after SS Korsakov. – 2017; 12 (Vol. 2): 65–9 (in Russ.)].
  52. Makhova A., Shich E., Kukes V. etal. Electroanalysis of cytochrome P450 3A4 catalytic properties with nanostructured electrodes: the influence of vitamin B group on diclofenac metabolism // BioNanoScience. – 2011; 1 (1–2): 46–52.
  53. Mahova A.A., Shumjantseva V.V., Shih E.V. i dr. Reguljatsija aktivnosti fermentov metabolizma lekarstvennyh preparatov – tsitohromov R450 3A4 i 2S9 – biologicheski aktivnymi soedinenijami // Molekuljarnaja meditsina. – 2013; 5: 49–53 [Makhova A.A., Shumyantseva V.V., Shikh E.V. et al. Regulation of the activity of drug metabolism enzymes – cytochromes P450 3A4 and 2C9 – biologically active compounds // Molecular medicine. – 2013; 5: 49–53 (in Russ.)].